BioCentury | Apr 18, 2019
Distillery Therapeutics

Plasmid-encoded toxin for targeted killing of antibiotic-resistant bacteria

DISEASE CATEGORY: Infectious disease INDICATION: Cholera; Gram-negative bacterial infection Cell culture, zebrafish and brine shrimp studies suggest a toxin-encoding plasmid could help treat infection by antibiotic-resistant Vibrio cholerae and other antibiotic-resistant Gram-negative bacteria. The plasmid...
BioCentury | Jan 28, 2019
Preclinical News

Unfolded protein response activates MYC in prostate cancer

A European team has linked the unfolded protein response to MYC signaling, lending weight to oncology strategies targeting the IRE1/XBP1 pathway, and identified prostate cancer as another indication for XBP1 inhibitors. A U.S. team including...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
BioCentury | Oct 10, 2018
Preclinical News

Quentis links ER stress, mitochondrial dysfunction with antitumor T cell activity

Researchers at Quentis Therapeutics Inc. (New York, N.Y.), Weill Cornell Medicine and Dana-Farber Cancer Institute uncovered a new mechanism of tumor immune evasion in which endoplasmic reticulum stress limits mitochondrial respiration and antitumor activity in...
BioCentury | Feb 27, 2018
Emerging Company Profile

Stressing out cancer

Quentis Therapeutics Inc. debuted with a $48 million series A round to develop potentially first-in-class therapies that inhibit the ER stress response, with the dual effect of killing tumor cells directly and unleashing immune cells...
BioCentury | Jan 17, 2018
Distillery Therapeutics


INDICATION: Huntington's disease (HD) Cell culture studies suggest promoting the expression of ATF4 and CTH could help treat HD. In a mouse striatal cell line expressing mutant HTT and cultured under HD-associated low cysteine conditions,...
BioCentury | Nov 1, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: October 2017

New Therapeutic Targets and Biomarkers: October 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Oct 19, 2017

Broad umbrella

In its $50 million tie-up with the Broad Institute of MIT and Harvard , Deerfield Management is looking to forge a new mold of partnership with an academic organization that allows it to efficiently survey early...
BioCentury | Oct 3, 2017
Distillery Therapeutics


INDICATION: Breast cancer Mouse studies suggest ATF3 inhibition plus chemotherapy could help treat metastases of breast cancer. In a mouse model of breast cancer treated with paclitaxel, ATF3 knockout decreased primary tumor growth and metastatic...
BioCentury | Jun 22, 2017
Translation in Brief

TERS talk

A UCSD group has added "transmissible ER stress (TERS)" to the list of cancer's survival strategies. In a study published this month in Science Signaling , the group showed cancer cells undergoing ER stress send soluble...
Items per page:
1 - 10 of 36